ProCE Banner Events

Share

Conference to Clinic Roundtable: Applying the Latest Data Developments for Therapies Targeting TROP-2 and TIGIT in Lung Cancer

Learn more about emerging strategies to improve outcomes in lung cancer through innovative therapies, including antibody–drug conjugates targeting TROP-2 and immune checkpoint inhibitors targeting TIGIT. Explore the latest clinical evidence on agents such as sacituzumab govitecan, datopotamab deruxtecan, and domvanalimab, including how to select appropriate patients, manage treatment-related toxicities, and integrate these therapies into evolving standards of care to help optimize patient outcomes.

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

Physicians ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Who Should Attend

This educational activity is intended for medical oncologists and other healthcare professionals who care for patients with lung cancer. 

Time and location

Tuesday, May 20, 2025

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Agenda

  • Welcome and Baseline Outcomes Assessment
    • Review of Unmet Needs With Current SoC in Patients With NSCLC and SCLC
  • Experts Analyze Emerging Data for ADCs and Immunotherapy Combinations: Show Me the Data
    • TROP-2 and TIGIT: Biologic Roles and Rationales as Therapeutic Targets in Lung Cancer
    • Key Data for TROP-2 ADCs presented at ELCC 2025
      • Emerging Data Targeting TROP-2: ADCs
      • Sacituzumab govitecan: TROP-2–directed ADC
      • Datopotamab deruxtecan: TROP-2–directed ADC
      • Sacituzumab tirumotecan: TROP-2–directed ADC
    • Key Data for Anti-TIGIT Agents Presented at ELCC 2025
      • Domvanalimab: Fc-silent anti-TIGIT mAb
      • Other anti-TIGIT agents
    • Expert Discussion
  • Applications for Targeting TROP-2 and TIGIT in SCLC: Show Me the Data
    • Sacituzumab Govitecan
      • BTD in second-line ES-SCLC after platinum-based chemotherapy
    • Ociperlimab
      • Data from phase II AdvanTIG-204
    • Tiragolumab
      • Data from phase III SKYSCRAPER-02
    • Expert Discussion
  • A Focus on Equitable Access: Clinical Trial Enrollment Strategies
    • Importance of Clinical Trials and Access to New Therapies for Patients With Lung Cancer
    • Expert Discussion
  • Audience Q&A

CME/CE Info

Goal Statement
This activity aims to improve learners' knowledge, confidence, and competence at integrating novel therapies targeting TROP-2 or TIGIT into the care of patients with lung cancer.

Target Audience
This educational activity is intended for medical oncologists and other healthcare professionals who care for patients with lung cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with lung cancer most likely to benefit from novel therapies targeting TROP-2 and TIGIT based on individual patient and tumor characteristics

  • Apply recently presented data evaluating the use of novel therapies targeting TROP-2 and TIGIT in lung cancer to clinical practice

  • Assess the eligibility of patients with lung cancer for enrollment on clinical trials of novel therapies targeting TROP-2 and TIGIT with the potential to enhance clinical outcomes

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/67167f3d10da3.png

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC

Supporter

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.